Array BioPharma, Inc. (ARRY)

ForceMajeure26 (73.75) Submitted: 3/03/08 2:16 PM : Start Price: $6.44 ARRY Score: 25.90

What we have in Array BioPharma is what we see in Exelixis - only a year two earlier. And if there is a "safer" way for most of us to play the biotech sector it is to get in very early with small amounts and add over time in small pieces.
The reason to get in early is fairly straightforward - Array has 10 drugs in development - the majority in Cancer and 3 that will treat Inflammation (I.E. anything -itis). Much like its older brother Exelixis, Array has partnered with the big boys - your Genentechs, Amgens, Celgene, Eli Lilly, etc.
With so many established players in the Biotech field willing to partner with Array, its stands to reason the company is producing some excellent compounds.
As Charly Travers and Brian Lawler have taught me, most of these compounds will not be approved by the FDA - but dont despair, because we only need 1 or 2 of these to make it. The risks remain high (and why I allocate small amounts even to promising biotechs) but the potential for multibagger returns is very evident.

Cheers!
Matt

Report this Post Replies: 0 | Reply